Preclinical News and Research

RSS
NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Micro-injector may help rapid development of new generation of drugs

Micro-injector may help rapid development of new generation of drugs

AMFm subsidized malaria drugs to be delivered soon

AMFm subsidized malaria drugs to be delivered soon

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Third quarter 2009 financial results announced by Synta Pharmaceuticals

Third quarter 2009 financial results announced by Synta Pharmaceuticals

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

New strategy to eliminate and eradicate malaria unveiled

New strategy to eliminate and eradicate malaria unveiled

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Health Canada approves the marketing of BioMimetic Therapeutics' Augment Bone Graft

Health Canada approves the marketing of BioMimetic Therapeutics' Augment Bone Graft

NIH awards $4 million research grant to AllTranz

NIH awards $4 million research grant to AllTranz

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

AMRI receives $750,000 milestone payment from Bristol-Myers Squibb

AMRI receives $750,000 milestone payment from Bristol-Myers Squibb

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

GICD, Stanford University collaborate to develop stem cell and regenerative medicine therapies

GICD, Stanford University collaborate to develop stem cell and regenerative medicine therapies

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Cambridge Research & Instrumentation launches  inForm image analysis software

Cambridge Research & Instrumentation launches inForm image analysis software

Ligand Pharmaceuticals amends license agreement with Exelixis

Ligand Pharmaceuticals amends license agreement with Exelixis

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.